The Serum Institute of India is taking another $150 million stake in Biocon Biologics, the biosimilar business of Biocon. The new investment adds to the $150 million the Serum Institute promised in September. Under the new deal, Biocon gets access to 100 million doses of vaccines annually plus distribution rights to Serum's vaccine portfolio.